Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.

Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE.

Reprod Sci. 2018 Jan 1:1933719118778801. doi: 10.1177/1933719118778801. [Epub ahead of print]

PMID:
29843577
2.

MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.

Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES.

Hum Pathol. 2018 Jun;76:133-140. doi: 10.1016/j.humpath.2018.02.019. Epub 2018 Mar 5.

PMID:
29518404
3.

Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9.

van Tienen LM, Mieszczanek J, Fiedler M, Rutherford TJ, Bienz M.

Elife. 2017 Mar 15;6. pii: e20882. doi: 10.7554/eLife.20882. Erratum in: Elife. 2017 Mar 30;6:.

4.

Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.

Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.

5.

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G.

Gynecol Oncol. 2017 Mar;144(3):459-467. doi: 10.1016/j.ygyno.2016.11.033. Epub 2017 Jan 13.

6.

Essential role of the Dishevelled DEP domain in a Wnt-dependent human-cell-based complementation assay.

Gammons MV, Rutherford TJ, Steinhart Z, Angers S, Bienz M.

J Cell Sci. 2016 Oct 15;129(20):3892-3902.

7.

Wnt Signalosome Assembly by DEP Domain Swapping of Dishevelled.

Gammons MV, Renko M, Johnson CM, Rutherford TJ, Bienz M.

Mol Cell. 2016 Oct 6;64(1):92-104. doi: 10.1016/j.molcel.2016.08.026. Epub 2016 Sep 29.

8.

Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.

Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE.

Eur J Gynaecol Oncol. 2016;37(2):199-203.

PMID:
27172745
9.

Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.

Ishiguro K, Zhu YL, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES.

J Transl Sci. 2016;2(2):117-124. Epub 2016 Mar 5.

10.

Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere.

Wilcken R, Zimmermann MO, Bauer MR, Rutherford TJ, Fersht AR, Joerger AC, Boeckler FM.

ACS Chem Biol. 2015 Dec 18;10(12):2725-32. doi: 10.1021/acschembio.5b00515. Epub 2015 Oct 1.

11.

An ancient Pygo-dependent Wnt enhanceosome integrated by Chip/LDB-SSDP.

Fiedler M, Graeb M, Mieszczanek J, Rutherford TJ, Johnson CM, Bienz M.

Elife. 2015 Aug 27;4. doi: 10.7554/eLife.09073.

12.

Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics.

Black JD, Altwerger GH, Ratner E, Lu L, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ.

Gynecol Obstet Invest. 2015 Jun 6. [Epub ahead of print]

PMID:
26067608
13.

Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.

Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Int J Cancer. 2015 Dec 1;137(11):2618-29. doi: 10.1002/ijc.29632. Epub 2015 Aug 18.

14.

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM.

Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24.

15.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD.

Gynecol Oncol. 2015 Jun;137(3):392-400. doi: 10.1016/j.ygyno.2015.03.008. Epub 2015 Mar 17. Review.

PMID:
25792179
16.

A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience.

Black JD, Roque DM, Pasternak MC, Buza N, Rutherford TJ, Schwartz PE, McCarthy S, Ratner E.

Int J Gynecol Cancer. 2015 Jun;25(5):792-7. doi: 10.1097/IGC.0000000000000431.

PMID:
25790042
17.

Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis.

Joo WD, Schwartz PE, Rutherford TJ, Seong SJ, Ku J, Park H, Jung SG, Choi MC, Lee C.

Ann Surg Oncol. 2015 Oct;22(11):3695-700. doi: 10.1245/s10434-015-4443-1. Epub 2015 Feb 18. Review.

PMID:
25691282
18.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Tumour Biol. 2015 Jul;36(7):5505-13. doi: 10.1007/s13277-015-3218-4. Epub 2015 Feb 11.

19.

Frailty, cognitive impairment, and functional disability in older women with female pelvic floor dysfunction.

Erekson EA, Fried TR, Martin DK, Rutherford TJ, Strohbehn K, Bynum JP.

Int Urogynecol J. 2015 Jun;26(6):823-30. doi: 10.1007/s00192-014-2596-2. Epub 2014 Dec 17.

20.

Feasibility, Sensitivity, and Specificity of Postprocedure Peritoneal Cytology.

Seagle BL, Dawson M, Samuelson R, Chacho MS, Rutherford TJ, Shahabi S.

Reprod Sci. 2015 Jul;22(7):808-13. doi: 10.1177/1933719114561551. Epub 2014 Dec 7.

PMID:
25488943
21.

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

Plamadeala V, Kelley JL, Chan JK, Krivak TC, Gabrin MJ, Brower SL, Powell MA, Rutherford TJ, Coleman RL.

Gynecol Oncol. 2015 Jan;136(1):94-8. doi: 10.1016/j.ygyno.2014.11.019. Epub 2014 Nov 25.

22.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD.

Clin Exp Metastasis. 2015 Jan;32(1):29-38. doi: 10.1007/s10585-014-9688-8. Epub 2014 Nov 15.

23.

Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD finger.

Miller TC, Rutherford TJ, Birchall K, Chugh J, Fiedler M, Bienz M.

ACS Chem Biol. 2014 Dec 19;9(12):2864-74. doi: 10.1021/cb500585s. Epub 2014 Oct 24.

24.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Br J Cancer. 2014 Oct 28;111(9):1750-6. doi: 10.1038/bjc.2014.519. Epub 2014 Sep 30.

25.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.

English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Cancer. 2015 Feb 1;121(3):403-12. doi: 10.1002/cncr.29062. Epub 2014 Sep 23.

26.

Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.

Ishiguro K, Lin ZP, Penketh PG, Shyam K, Zhu R, Baumann RP, Zhu YL, Sartorelli AC, Rutherford TJ, Ratner ES.

Biochem Pharmacol. 2014 Oct 1;91(3):312-22. doi: 10.1016/j.bcp.2014.08.006. Epub 2014 Aug 15.

27.

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD.

Gynecol Oncol. 2014 Oct;135(1):142-8. doi: 10.1016/j.ygyno.2014.08.006. Epub 2014 Aug 12.

PMID:
25124161
28.

Impact of body mass index on surgical outcomes and analysis of disease recurrence for patients with endometrial cancer undergoing robotic-assisted staging.

Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA.

Int J Gynecol Cancer. 2014 Jul;24(6):1118-25. doi: 10.1097/IGC.0000000000000156.

PMID:
24927247
29.

T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.

English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Cancer Med. 2014 Oct;3(5):1256-65. doi: 10.1002/cam4.274. Epub 2014 Jun 2.

30.

Structure of the SAS-6 cartwheel hub from Leishmania major.

van Breugel M, Wilcken R, McLaughlin SH, Rutherford TJ, Johnson CM.

Elife. 2014 Jan 1;3:e01812. doi: 10.7554/eLife.01812.

31.

Evolutionary adaptation of the fly Pygo PHD finger toward recognizing histone H3 tail methylated at arginine 2.

Miller TC, Mieszczanek J, Sánchez-Barrena MJ, Rutherford TJ, Fiedler M, Bienz M.

Structure. 2013 Dec 3;21(12):2208-20. doi: 10.1016/j.str.2013.09.013. Epub 2013 Oct 31.

32.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.

Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.

Clin Exp Metastasis. 2014 Jan;31(1):101-10. doi: 10.1007/s10585-013-9614-5. Epub 2013 Sep 5.

33.

Expression of O6-Methylguanine-DNA Methyltransferase Examined by Alkyl-Transfer Assays, Methylation-Specific PCR and Western Blots in Tumors and Matched Normal Tissue.

Ishiguro K, Shyam K, Penketh PG, Baumann RP, Sartorelli AC, Rutherford TJ, Ratner ES.

J Cancer Ther. 2013 Jun;4(4):919-931.

34.

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy.

Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD.

Br J Cancer. 2013 Jul 23;109(2):462-71. doi: 10.1038/bjc.2013.315. Epub 2013 Jun 27.

35.

Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD.

Cancer. 2013 Jul 15;119(14):2582-92. doi: 10.1002/cncr.28017. Epub 2013 Apr 12.

36.

Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.

Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9. doi: 10.1016/j.ajog.2013.04.017. Epub 2013 Apr 10.

PMID:
23583215
37.

An essential role for the ATG8 ortholog LC3C in antibacterial autophagy.

von Muhlinen N, Akutsu M, Ravenhill BJ, Foeglein Á, Bloor S, Rutherford TJ, Freund SM, Komander D, Randow F.

Autophagy. 2013 May;9(5):784-6. doi: 10.4161/auto.23698. Epub 2013 Feb 22.

38.

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.

39.

Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.

Vogel SM, Bauer MR, Joerger AC, Wilcken R, Brandt T, Veprintsev DB, Rutherford TJ, Fersht AR, Boeckler FM.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16906-10. doi: 10.1073/pnas.1215060109. Epub 2012 Oct 3.

40.

LC3C, bound selectively by a noncanonical LIR motif in NDP52, is required for antibacterial autophagy.

von Muhlinen N, Akutsu M, Ravenhill BJ, Foeglein Á, Bloor S, Rutherford TJ, Freund SM, Komander D, Randow F.

Mol Cell. 2012 Nov 9;48(3):329-42. doi: 10.1016/j.molcel.2012.08.024. Epub 2012 Sep 27.

41.

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).

Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, Schwartz PE.

J Surg Oncol. 2013 Feb;107(2):195-200. doi: 10.1002/jso.23171. Epub 2012 May 30.

PMID:
22648987
42.

Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women.

Cross SN, Ratner E, Rutherford TJ, Schwartz PE, Norwitz ER.

Rev Obstet Gynecol. 2012;5(1):2-8.

43.

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.

Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, Abu-Khalaf M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Br J Cancer. 2012 Apr 24;106(9):1543-50. doi: 10.1038/bjc.2012.132.

44.

HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.

Guzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, Cocco E, Betti M, Todeschini P, Gasparrini S, Schwartz PE, Rutherford TJ, Angioli R, Pecorelli S, Santin AD.

Int J Gynecol Pathol. 2012 May;31(3):211-21. doi: 10.1097/PGP.0b013e31823bb24d.

45.

Halogen-enriched fragment libraries as leads for drug rescue of mutant p53.

Wilcken R, Liu X, Zimmermann MO, Rutherford TJ, Fersht AR, Joerger AC, Boeckler FM.

J Am Chem Soc. 2012 Apr 18;134(15):6810-8. doi: 10.1021/ja301056a. Epub 2012 Apr 5.

46.

An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.

de la Roche M, Rutherford TJ, Gupta D, Veprintsev DB, Saxty B, Freund SM, Bienz M.

Nat Commun. 2012 Feb 21;3:680. doi: 10.1038/ncomms1680.

47.

An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers.

Nelson WK, Formica RN Jr, Cooper DL, Schwartz PE, Rutherford TJ.

J Oncol Pharm Pract. 2012 Sep;18(3):323-32. doi: 10.1177/1078155211435714. Epub 2012 Feb 13.

PMID:
22331238
48.

Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.

Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD.

Gynecol Oncol. 2012 Apr;125(1):231-6. doi: 10.1016/j.ygyno.2011.12.446. Epub 2011 Dec 29.

49.

An ankyrin-repeat ubiquitin-binding domain determines TRABID's specificity for atypical ubiquitin chains.

Licchesi JD, Mieszczanek J, Mevissen TE, Rutherford TJ, Akutsu M, Virdee S, El Oualid F, Chin JW, Ovaa H, Bienz M, Komander D.

Nat Struct Mol Biol. 2011 Dec 11;19(1):62-71. doi: 10.1038/nsmb.2169.

50.

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.

Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

Supplemental Content

Loading ...
Support Center